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Abstract 
The most commonly used techniques for the in vivo evaluation of the cellular 
immune response include intracutaneous testing with microbial recall antigens 
or sensitization with neoantigens. The reliability of these tests for the individual 
patient usually is low due to the lack of standardization and quantification. 
Moreover only the efferent branch of the immune response can be judged. 
The dinitrochlorobenzene-contact allergy time (DNCB-CAT) is a quantita-
tive approach for the assessment of the cellular immune response. 2% DNCB-
ointment is applied on the upper arm in a 1 cm 2 area. On the following days 
patch-testing with 0.05% DNCB-ointment is done on the homolateral forearm 
in alternating localizations t i l l an allergic contact dermatitis reaction appears. 
As assessed in patients with malignant melanoma ( M M , n=\\5) and with 
lymphoproliferative disorders (LD, η = 25), the DNCB-CAT correlates with 
the age of the patients and can be expressed by a formula given by the age 
(years) χ factor ( M M = 0.16; L D = 0.17) + constant figure ( M M = 5.5; 
L D = 4.3). There was no significant difference between the two groups or sub­
groups investigated. 
By DNCB-CAT quantitative analysis of the cellular immune response in 
vivo is possible. It is an appropriate model for further investigations of the 
cellular immunity under different clinical, histological, prognostic, and thera­
peutic aspects. 
Introduction 
Immune status is an i l l defined term, reflecting the capacity of the organism to 
exhibit immunologic defense mechanisms following antigenic stimulation. 
Evaluation of the immune status may be of interest in various disciplines, such 
as oncology, hematology, and transplantation medicine. In dermatology alter­
ation of the immune status has been described in sarcoidosis, leprosy, atopic ec­
zema, collagenosis, chronic infectious diseases, AIDS, malignant neoplasms 
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(including squamous and basal cell carcinoma, malignant melanoma and 
lymphoma), and several other conditions [1,5]. 
Reports in the literature are controversial. For example in malignant mela­
noma, cell-mediated immunity assessed by recall antigens or by neoantigens 
has been claimed to be normal [22], impaired [19], and even increased [20]. The 
reasons for the contradictory results are manifold. They may be due to the 
method applied, to the patient and his disease, or to the test material or anti­
gens used: Firstly the various in vitro and in vivo tests for the assessment of im­
mune status can scarcely be compared since they reflect different functional 
capacities of the immune system. Secondly the contradictory results may be re­
lated to the patient and his disease in that factors claimed to modulate the im­
mune response, like atopy [15, 16], clinical stage of tumoral diseases [14], sex 
[11, 17], or surgical stress [3], have been neglected in many of the reports on the 
immune status of patients tested. Thirdly the in vivo methods used are not stan­
dardized with respect to either the test procedure and the number and type of 
antigens tested or the evaluation of the test reaction [12]. Comparison of six re­
call antigens provided by two different manufacturers tested simultaneously in 
each of 20 patients revealed different test reactions in 10% for tuberculin, in 
20%; for trichophytin, in 30% for diphtheria, in 35% for streptococci or candidin, 
and in more than 50% for tetanus antigen (Table 1). In the same group of pa­
tients there was complete anergy in one patient tested with seven recall antigens 
from manufacturer Μ and in another patient tested with antigens from manu­
facturer B. The mean numbers of positive reactions in the two groups were 40% 
and 25% respectively (Table 2). 
One step towards standardization and quantification of delayed type hy­
persensitivity tests for the evaluation of immune status is the multitest. The ap­
plication of seven recall antigens and the control is standardized; the result is 
Table 1. Comparison of six recall antigens from two different 
manufacturers tested in each of 20 patients 
Recall antigen % discordance 
Tuberculin 10% 
Trichophytin 20% 
Diphtheria 30% 
Streptococci 35% 
Candidin 35% 
Tetanus 55% 
Table 2. Comparison of DTH reactions of recall antigens from 
two different manufacturers (M and B) (n = 20) 
Manufacturer Μ Β 
Number of recall antigens 7 11 
Complete anergy 5% (1) 5% (1) 
Mean number of positive reactions 40% (3/7) 25% (3/11) 
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7 Antigens, 1 Control 
Control 
(glycerol) 
Score (mm) S 21 10) ? 15 (i= 5) 
Quantitative Evaluation 
1. Sum of mean of 
a + b 
diameters • of positive 
(> 2 mm) reactions 
2. Number of positive 
reactions 
Fig. 1. Multitest Merieux with recall antigens 
given in a score calculated from the number and the sum of diameters of posi-
tive test reactions (Fig. 1). The disadvantage, as with all tests using recall anti-
gens, is that the multitest depends partly on regional vaccination programs, on 
geographic and epidemic factors, and on the sex of the patient without corre-
lation to age [13]. Therefore testing with neoantigens like DNCB would seem 
more reliable [7]. 
Potential hazards of therapeutic use of dinitrochlorobenzene (DNCB), like 
mutagenicity or cross-reaction with other substances, can be ignored when it is 
used as a test allergen [2, 6, 8, 21]. The common procedure for DNCB testing 
consists in the application of a toxic 2% concentration of DNCB on the arm and 
a threshold challenge test with DNCB in various concentrations 2 — 4 weeks 
later. This neglects two important factors: 
1. Only some of the patients will be sensitized at the time of the challenge test. 
2. I f the challenge test is performed when more time has elapsed since the first 
contact, the degree of sensitization wil l be slowly fading, so that determi-
nation of the threshold dose will not quantitatively reflect the immune status 
of the patient [10]. 
The disadvantage of all classical in vivo tests of the immune status — in-
tracutaneous with recall antigens or epicutaneous with neoantigens - is the fact 
that only the efferent l imb of the immune reaction process is measured, not the 
afferent l imb, which is more complex, more important, and affords greater in-
sight into the integrity or disturbance of the immune system [9]. 
Method and Patient Material 
We tried to evaluate the complete process of development of hypersensitivity, 
as expressed by the time needed by the patient to build up an immunological 
reaction to DNCB, including both the afferent and the efferent l imb (Fig. 2). A 
patch with 2% DNCB was applied on day 0 on a 1 cm 2 area of the upper arm. 
Subsequently 0.05% DNCB was applied daily on the forearm in alternating lo-
cations. The day when an allergic reaction appeared was registered. One week 
later a challenge test was performed in order to determine the threshold dose, 
using various concentrations of DNCB, from 0.001% to 0.05%. 
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Table 3. DNCB-CAT test results in 115 patients with malignant melanoma 
Patients DNCB-CAT (days) 
No. Mean age Mean Shortest Longest 
Type SSM 54 54 14 6 58 
NM 48 48 15 6 62 
LMM 3 59 23 10 49 
ALM 4 51 10 8 12 
Stage I 103 51 14 6 62 
II 8 47 14 9 25 
III 4 51 13 10 16 
Level II 10 56 14 8 30 
III 40 52 17 8 62 
IV 46 51 13 6 31 
V 5 51 12 10 14 
Prognostic 0-1 29 51 14 8 62 
index (18) 1.1-13 46 48 15 6 58 
> 13 21 56 14 9 31 
Abbreviations: SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo 
maligna melanoma; ALM, acrolentiginous melanoma 
2% D N C B * 
upper arm 
43 h 
0.05% DNCB * 
lower arm 
24 h 
Μ I I I I Μ Μ 
10 
0 0 0 0 .0 0 J3 0 0 JÖ 0 JÖ + 
Reaction 
Fig. 2. DNCB-CAT for testing the immune status. * in Eucerin anhydricum 
Days 
Threshold testing 
0.04 0.005 
0.02 0.002 
0.01 0.001% DNCB 
The test was applied to 115 patients with malignant melanoma (46 men, 69 
women, age range 19-79 years, mean 51 years). Further information on their 
clinical features, stage, level, and prognostic index (PI [18]) is given in Table 3. 
Results 
The figures given in Table 3 illustrate the DNCB contact-allergy time (DNCB-
CAT) in various subgroups of malignant melanoma patients. The shortest time 
measured (6 days) was found in one patient with superficial spreading mela-
noma (SSM) and in another with nodular melanoma (NM). Eleven patients 
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showed a DCNB-CAT of longer than 20 days; the longest, 62 days, occurred in 
a patient with stage I , level I I I , low risk (prognostic index below 1) N M . 
No significant correlation could be detected between the DNCB-CAT in 
various clinical types of malignant melanoma (SSM, N M , lentigo maligna 
melanoma, acrolentiginous melanoma) and stage (I —II I ) , level ( I I —V), or prog­
nostic index score ( < 1, 1.1 - 13, > 13). 
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Fig. 3. Age-dependent regression curve of DNCB-CAT in malignant melanoma and 125% 
percentile (—) 
49 
2 _ i _ 
18 16 
Γ 
50 75 100 125 150 
Grade of immunodeficiency 
I 
200 
Normal ι I I I I I 
Β % DNCB-CAT 
Age x 0.16 + 5.5 
I Y 
Fig. 4. DNCB-CAT exceeding the age-dependent calculated average: grades I - I V of immune 
deficiency 
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The most important finding was a strong correlation between DNCB-CAT 
and age of the patient. The expected DNCB-CAT was found to equal the age of 
the patient multiplied by a constant factor (0.16) plus a constant figure (5.5). 
Thus the DNCB-CAT in a 20-year-old patient is on average about half that ex­
pected in an 80-year-old patient (Fig. 3). Of the 115 patients, 69% (n = 79) 
exhibited a DNCB-CAT below the expected value as calculated by the above 
means. On the other hand 16% (n = 18) exceeded the expected figure by more 
than 25%, 11% by more than 50%, and 5% by more than 100% (TabTe 4, Fig. 4). 
Table 4. Grading of immune deficiency by DNCB-CAT 
Grade % exceeding No. of patients % 
normal value 
(agexO.16 + 5.5) 
0 0 79 69 
(normal) 
I 25% 18 16 
11 < 50% 5 4 
III 300% 7 6 
IV > 100% 6 5 
Table 5. Details of melanoma patients (n = 18) exhibiting an increased DNCB-CAT 
Immuno­ % DNCB- Age MM Stagea Level Depth P I b Fol- Stagec 
deficiency CAT (years) (type) of in­ lowup 
grade calcu­ vasion (years) 
lated (mm) 
II 136 42 SSM II _ — — 3.5 0 
125%-150% 140 41 SSM I II 0.27 < 1 1 0 
140 41 SSM I II 0.85 3 3 0 
142 43 SSM I II 0.27 < 1 2 0 
146 45 SSM II IV - 33 4.5 + 
III 152 42 SSM I IV 1.1 5 2 0 
151%-200% 152 74 NM I IV 1.1 5 3 + 
156 21 NM II V - - 0.2 + 
166 50 SSM I III 0.45 < 1 3 0 
168 46 NM I III 0.48 2 3.5 0 
177 52 NM II IV 5.1 82 1.5 0 
184 68 NM I IV - 32 3 ΙΙ/0 
IV 203 56 SSM I II 0.68 < 1 2 0 
> 200% 208 42 ALM I IV 3.3 3 2 + 
248 54 SSM I III 1.37 5 2.5 0 
295 67 LMM I III 1.2 13 4 0 
365 69 NM I III 0.43 < 1 3 0 
433 47 SSM 1 III - 9 3 0 
a At time of diagnosis 
b Prognostic index [18] 
c At end of follow-up 
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Table 6. DNCB-CAT and multitest results in 15 patients with 
malignant melanoma 
Multi- Normal Pathologic 
test 
DNCB-CAT 
Normal 9 (60%)a 3 (20%)b 
Pathologic 2(13%)b 1 (7%)a 
a Concordance between tests = 67% 
b Discordance between tests = 33% 
Table 7. Correlation between DNCB-CAT and DNCB 
threshold concentration in 13 melanoma patients 
DNCB-CAT a Degree of hypersensitivity 
High b Low c 
+ 2 (15%)d 8(62%)e 
— 1 (8%)e 2 (15%)d 
a + = normal or below; - = > 25% above normal 
b 0.005%, 0.002%, or 0.001 % DNCB 
c 0.04%, 0.02%, or 0.01% DNCB 
d Concordance = 30% 
e Discordance = 70% 
I f the patients whose DCNB-CATs were higher than expected were cat­
egorized into four immunodeficiency groups (1= 101%-125% of normal age-
related DNCB-CAT; 11= 126%- 150%ΓHI = 151% —200%; IV > 200%) and the 
patients of groups I I - I V were listed in order of their DNCB-CAT (Table 5), no 
correlation was seen either with the type of melanoma or with stage, level, 
prognostic indices, or survival within the different categories. 
In 15 patients we compared the result of the Merieux multitest with the 
DNCB-CAT test. A multitest score below 5 in women and below 10 in men and 
a DNCB-CAT exceeding the expected value by more than 25% were considered 
pathologic. Concordance between the multitest and the DCNB-CAT test was 
found in about two-thirds of the patients tested (Table 6). 
Correlation between the DNCB-CAT and the degree of sensitization ex­
pressed by the threshold concentration of DNCB was found in only about one-
third of the 13 patients tested (Table 7). 
Discussion 
Abnormalities of the cell-mediated immune status have been reported in a 
variety of dermatoses, including inflammatory and proliferating disorders [5]. It 
has been speculated that tumor induction and tumor growth are controlled by 
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specific immune reactions against tumor cells, including enhancing and block­
ing mechanisms. However, there is little evidence that, for example, PHA 
stimulation of peripheral lymphocytes, the type and degree of the peritumoral 
infiltrate [4], or reactivity against recall antigens or neoantigens provide any 
reliable information as to the induction and growth of solid tumors. Neverthe­
less, in advanced stages of tumoral diseases with widespread metastases the im­
mune system may be severely affected and a single test may elucidate dys-
functioning delayed type sensitivity provided the procedure is standardized and 
individual factors (e.g., age) are considered. Moreover it is important that the 
afferent and efferent limbs of the delayed type reactivity are measured. There­
fore neoantigens are preferable to recall antigens. 
The DNCB-CAT test is recommended as a standardized test for the as­
sessment of immune status since it is simple, covers the complete process of 
building up delayed type hypersensitivity, and considers the most important in­
dividual factor, namely age. When using the DNCB-CAT test, grades ( I - I V ) of 
immunodeficiency can be differentiated in accordance with the percentage by 
which the actual DNCB-CAT exceeds the average-figure calculated for the in­
dividual age group. 
Summary 
The DNCB-CAT test is a quantitative approach for the assessment of the cellu­
lar immune response. 2% DNCB ointment is applied on the upper arm over a 
1 cm 2 area. On subsequent days patch testing with 0.05% DNCB ointment is 
done on the homolateral forearm until an allergic contact dermatitis reaction 
appears. By this the afferent and the efferent l imb of the delayed hypersensi­
tivity reaction is measured. 
In a group of 115 patients with solid tumors (malignant melanomas) 
DNCB-CAT correlated with the age of the patient and could be expressed by 
the following equation: 
[DNCB-CAT = Age (years) χ 0.16] 4- 5.5 
Deviations from the calculated agedependent regression curve were cate­
gorized into grades I - IV of immunodeficiency. 
DNCB-CAT is an appropriate model for quantitative age-related analysis 
of cellular immune responsiveness in relation to various clinical, histologic, 
prognostic, and therapeutic factors. 
References 
1. Ahmed AR, Blose DA (1983) Delayed-type hypersensitivity skin testing. Arch Dermatol 
119:934-945 
2. Black HS, Castrow F F , Gerguis J (1985) The mutagenicity of dinitrochlorobenzene. Arch 
Dermatol 121:348-349 
238 G. Burg et al. 
3. Bröcker EB, Macher Ε (1981) Der Einfluß von Narkose und Operation auf das Im-
munsystem. Klin Wochenschr 59:1291-1301 
4. Burg G, Kohdam M, Kaudewitz D, Detmar U, Mason D Y (1984) Plasma cells accumulat-
ing around epidermal neoplasms. Immunoenzymatic staining of paraffin sections. Mac-
Donald D (ed) Immunodermatology. Butterworth, London, pp 167—171 
5. Burg G, Rehle R (1981) Immunological work up. In: Ring J, Burg G (eds) New trends in 
allergy. Springer, Berlin Heidelberg New York, pp 115 -128 
6. Djawari D, Körner Ε, Haneke Ε (1980) Kreuzallergien nach Sensibilisierung mit Dini-
trochlorbenzol (DNCB) Hautarzt 31 :F 198-202 
7. Friedmann PS, Moss C, Shuster S, Simpson JM (1983) Quantitation of sensitization and 
responsiveness to dinitrochlorobenze in normal subjects. Br J Dermatol 109 [Suppl]:86-88 
8. Happle R (1985) The potential hazards of dinitrochlorobenzene. Arch Dermatol 
121:330-331 
9. Knop J (1984) Immunologische Grundlagen des allergischen Kontaktekzems. Hautarzt 
35:617-622 
10. Magnusson B, Kligman AM (1970) Allergie contact dermatitis in the guinea pig. Thomas, 
Springfield 
11. Marcano NB, Rivas A, Figarella EV, Bianca I, Penchaszadeh G K , Perez-Rojas G, Bianco 
NE (1982) Cell-mediated effector mechanisms in aging humans. Int Archs Allergy Appl 
Immunol 69:7 - 11 
12. Mayenburg JV, Heymer B, Düngemann Η, Schleifer K H , Seidl HP, Galle J, Neiß A, 
Borelli S (1980) Hautreaktionen gegen isolierte bakterielle Zellwandkomponenten ins-
besondere bakterielle Peptidoglycane. Ζ Hautkr 55:710-733 
13. Multitest Merieux (1984) Institut Merieux, Norderstedt 
14. Pritchard DI, Ritts RE, Taylor WF, Miller G C (1978) A prospective study of immune re­
sponsiveness inhuman melanoma. Cancer 41:2165-2173 
15. Rajka G (1968) Delayed dermal and epidermal reactivity in atopic dermatitis (prurigo 
Besnier). Acta Dermatol Venereol 48:186-191 
16. Rajka G, Barlinn C (1979) On the significance of the trichophytin reactivity in atopic der­
matitis. Acta Dermatol Venereol 59:45-47 
17. Rosenthal M, Steinmann A (1978) Lebensalter und Immunität. Dtsch Med Wochenschr 
103:409-412 
18. Schmoeckel C, Kaviani Nejad K, Braun-Falco Ο (1980) Der prognostische Index beim 
malignen Melanom. Pathologie 1:71-78 
19. Seigier HF, Stringleton WW, Metzger RS, Buckley CE, Bergoc PM, Miller DS, Fetter BF, 
Phaup MB (1972) Non-specific and specific immunotherapy in patients with melanoma. 
Surgery 72:162-174 
20. Stenger D, Delbrück Η, Krumrey Κ, Zaun Η (1983) Standardisierte Recall-Anti-
gentestung bei Patienten mit malignem Melanom, endogenen Ekzematikern und Ge­
sunden. Ζ Hautkr 58:293-304 
21. Strick RA (1983) Lack of cross-reaction between DNCB and chloramphenicol. Contact 
Dermatitis 9:484-487 
22. Ziegler JL, Lewis MG, Luyombya J Lus, Kiryaboire JWM (1969) Immunologic studies in 
patients with malignant melanoma in Uganda. Br J Cancer 23:729-734 
